Agios Pharmaceuticals, Inc.(AGIO)

Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership.

Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.

AGIO $33.60
Snapshot
$33.60
52-Week Range
$22.24 – $46.00
YTD
+23.62%
IV Rank (30D)
24.66
Straddle Price
$6.28
P/C Vol Ratio
17.57
Market Cap
$2.0B
Fair Value
MODEL: LONG

A blended fair-value estimate combining up to six valuation methods. Each method is weighted by how well it fits the company — DCF down-weights for unprofitable names; DDM only fires for steady dividend payers; comparables down-weight when peer multiples disagree.

  • DCF (quality-aware) — projects free cash flow with a horizon that scales to business quality. True compounders (quality 6/6) get 10 years explicit + 10 years fade before terminal; cyclical/struggling names (quality 0-1) get a 5-year terminal cliff. Quality is scored from ROE, gross margin, growth, FCF margin, debt load, and FCF consistency — the same factors that drive market premium for compounders.
  • Market-Implied Growth (in Model Inputs) — reverse-DCF that answers "what growth rate is the market pricing in?". Lets you sanity-check the deviation: if implied growth is plausible for the business, the model's bearish flag may be wrong; if implausible, the market may be over-extrapolating.
  • DDM (Gordon Growth Dividend Model) — values the stream of future dividends. Only used when trailing yield ≥ 2% and dividend payments are stable — below that the dividend is a token payout and Gordon (which values only the dividend stream) systematically underprices growth names, so those route to DCF + comparables + market anchor instead.
  • P/E, EV/EBITDA, P/B, P/S — applies the peer-group median multiple to this company's per-share metric. Peers come from the same set as the "Related symbols" card. Earnings/sales metrics are forward-tilted by the company's recent revenue growth (capped at 25%) so they're comparable to peers' growth-embedded multiples — mimics how analysts use NTM rather than TTM. Per-multiple weights are biased by company quality (e.g. P/B down-weighted for asset-light tech).
  • Market Anchor (SMA50) — the 50-day moving average, weighted by recent trading-range stability (tighter Bollinger bands → higher weight). Captures information fundamentals miss (forward consensus, sentiment, supply/demand) — but only when recent trading is steady enough that the market has converged on a view. During wild breakouts or breakdowns the anchor's weight collapses.
  • Options Expected (B-L 30d) — the risk-neutral expected stock price at 30-day options expiration, derived from the full implied-volatility surface via Breeden-Litzenberger (second derivative of call price wrt strike → implied PDF, then E[S_T]). Forward-looking, captures all options-implied information (smile, skew, term structure) in one number. Weighted by chain liquidity. SP500-only at present (pre-computed daily). Backtest evidence: adds modest alpha across most bucket × holding combos.
  • Blended value — weighted average. Confidence reflects how many methods fired and how tight peer dispersion is.
  • Deviation pill — green when blended FV ≥ 10% above current price (undervalued); red when ≥ 10% below; grey otherwise.
10-yr Treasury (rf)4.80%
Beta vs SPY1.25
Cost of Equity (CAPM)11.68% (VRP-adj)
WACC11.14%
Volatility Risk Premium+38.8pp (IV − HV30), ERP adj +50bps
Effective Tax Rate21.0%
Rev. Growth (YoY, DCF input)+30.0%
DCF Horizon10 years explicit + fade
Forward Tilt (NTM/TTM)×1.10 (applied to P/E, EV/EBITDA, P/S)
Free Cash Flow (TTM)$-0.4B
Return on Equity (TTM)-40.1%
Book / Price52.1% — banking bias active (P/B is primary)
Gross Margin (TTM)92.0%
FCF Margin (TTM)-371.4%
Debt / Equity0.00
Quality Score3/6 — normal (10y DCF)
SMA 50$35.42 (Market Anchor value)
SMA 20 / Bollinger Mid$33.76
Bollinger Width / SMA2020.2% (drives anchor stability)
Net Debt$-0.1B
Market Cap$2B
Peers used for multiples: ABT, PFE, REGN (SIC-code peers; ETF co-membership was sector-incoherent)
Model Conviction
11%
20-Day Fair Value
≈ by Oct 12, 2026
$32.39
α -3.6% rank 63%
40-Day Fair Value
≈ by Nov 10, 2026
$34.03
α +1.3% rank 51%
60-Day Fair Value
≈ by Dec 9, 2026
$33.92
α +1.0% rank 55%
MethodImplied PriceWeightDetail
DCF n/a 0%
DDM (Gordon) n/a 0%
Peer P/E n/a 0% median 33.6× · 3 peers
Peer EV/EBITDA n/a 0% median 19.1× · 3 peers
Peer P/B $45.88 22% median 2.6× · 3 peers
Peer P/S $7.22 22% median 3.9× · 3 peers
Market Anchor (SMA50) $35.42 56% stability 49% (BB-width)
Options Expected (B-L 30d) n/a 0%
As of 2026-09-11 · updated
Info
Industry (SIC)
PHARMACEUTICAL PREPARATIONS (2834)
Exchange
XNAS
Market Cap
$2.0B

Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and …

Summary
composite
No summary data available for this symbol yet.

Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.

Chart
Seasonality
MonthAvg ReturnYears of Data
Jan +2.05% 6
Feb +6.40% 6
Mar -3.77% 6
Apr -2.79% 6
May +5.93% 6
Jun +9.06% 6
Jul -1.36% 6
Aug +2.28% 6
Sep -2.01% 6
Oct +0.42% 5
Nov -1.68% 5
Dec -12.23% 5
Technical Indicators

Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.

Trend Indicators
  • SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
  • EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
  • MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
  • ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
  • +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
  • RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
  • Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
  • Williams %R — inverted scale: <−80 oversold, >−20 overbought.

Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.

Volume & Volatility
  • Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
  • OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
  • Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
  • ATR / True Range — average daily $ move; sizing and stop-loss reference.
  • HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.

Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →

Trend Indicators

SMA 20: $33.76
SMA 50: $35.35
SMA 200: $30.59
Current: $33.60
EMA 12: $33.72
EMA 26: $33.87
MACD: -0.1443 | Signal: 0.0796
BEARISH
ADX (14): 10.39
RANGE
+DI: 21.96
−DI: 17.77

Momentum Oscillators

RSI (14): 48.29
NEUTRAL
Stoch %K: 54.90
Stoch %D: 49.68
Williams %R: -56.44

Volume & Volatility

BB Upper: $34.91
BB Lower: $32.61
NEUTRAL
OBV: 13,403,165
Vol SMA 20: 853,700
Vol ROC: -25.09%
ATR: $1.45
True Range: $0.96
HV 20: 34.3%
HV 30: 42.4%
HV 60: 54.9%

Data Summary

Data Points: 500
Last Updated:
Date Range: 2024-09-13T00:00:00 – 2026-09-11T00:00:00
AI Analysis

Choose Frenzy-Fast™ for quick analysis or Frenzy-Pro™ for comprehensive analysis.

Analysis includes technical indicators, news sentiment, risk assessment, and specific price levels to watch.

News
Earnings History
8 of 8 under expected move
Avg Expected Move
12.06%
Avg Actual Move
3.51%
Each row pairs the pre-earnings straddle-implied expected move with the realized close-to-close move. Sorted oldest first.
Earnings Date Timing Expected Move Actual Move Ratio Outcome
2024-10-31 Pre-Market 10.26% 5.90% 0.58x Within
2025-02-13 Pre-Market 14.17% 1.49% 0.11x Within
2025-05-01 Pre-Market 7.43% 3.64% 0.49x Within
2025-07-31 After-Close 11.22% 5.96% 0.53x Within
2025-10-30 Pre-Market 13.82% 2.91% 0.21x Within
2026-02-12 Pre-Market 15.68% 1.56% 0.10x Within
2026-04-29 After-Close 12.57% 0.18% 0.01x Within
2026-07-30 Pre-Market 11.35% 6.46% 0.57x Within
Options Activity
IV Rank (30D)
24.66
IV Rank (7D)
100
Avg IV
84.3%
Straddle (30D)
$6.28
Straddle (7D)
$1.85
P/C Volume
17.57
Spread Scanner GPU

Each spread is ranked by a composite score built in three stages. Full documentation →

Stage 1 — Base Score (GPU scanner)

score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.

Stage 2 — Skew Adjustment (±25% cap)

RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.

Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
  • RSI <40 bullish / >60 bearish
  • MACD crossover + histogram trend
  • Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
  • Stochastic %K <20 / >80
  • Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
  • Blended ATR + straddle expected-move penalty
  • Bollinger Band signal (+ counter-trend penalty)
  • BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
  • IV rank ≥ 75 → strong boost for credit spreads
  • IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
  • Min open interest across all legs
  • OI < 100 → −0.10 · OI < 500 → −0.05

score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →

Enter a ticker to scan for optimal spread opportunities.

Evaluates all bull put, bear call, iron condor, and calendar spread combinations using GPU-accelerated analysis.

Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Metric:
Wing vs ATM
IV(put wing) − IV(ATM), in vol points

How much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.

  • Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
  • Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
  • Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
  • Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each side

Which side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.

  • Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
  • Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
  • Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
  • Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Reading them together

Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:

  • High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
  • Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
  • Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d
pts EXTREME
ATM — / Wing —
30 DTE / 10d
pts EXTREME
ATM — / Wing —

Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.

Volatility Surface

Enter a ticker to render the implied volatility surface.

Volatility Smile

Enter a ticker to render the implied volatility smile.

IV Rank (7 DTE)
IV Rank (30 DTE)
Straddle Price (30 DTE)
Beta Analysis
Beta (1Y vs SPY)
0.54
Correlation (SPY)
9.1%
0.01
Ann. Volatility
76.5%
SPY Volatility
12.8%

Low volatility - stock moves less than market

Beta & Alpha Over Time
Institutional Ownership (13F)
Latest filings — 2026-06-30
Diluted shares outstanding: 58,595,598 (as of 2026-06-30)

Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.

  • Shares — long equity positions in this name, aggregated across share classes.
  • Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
  • % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
  • Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.

Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.

244 filers65,432,207 shares$2.31B value111.67% of float
# Filer Shares Value % of Total % of Float Period
1 BlackRock, Inc. Custodian 6,455,997 $239.58M 10.37% 11.02% 2026-06-30
2 VANGUARD GROUP INC Custodian 5,594,353 $152.28M 6.59% 9.55% 2025-12-31
3 STATE STREET CORP 3,533,633 $131.14M 5.68% 6.03% 2026-06-30
4 Lynx1 Capital Management LP 3,408,937 $126.51M 5.47% 5.82% 2026-06-30
5 D. E. Shaw & Co., Inc. Custodian 3,107,005 $115.30M 4.99% 5.30% 2026-06-30
6 VANGUARD PORTFOLIO MANAGEMENT LLC 2,898,197 $107.55M 4.65% 4.95% 2026-06-30
7 VANGUARD CAPITAL MANAGEMENT LLC 2,681,845 $99.52M 4.31% 4.58% 2026-06-30
8 ARMISTICE CAPITAL, LLC 2,400,000 $89.06M 3.85% 4.10% 2026-06-30
9 Erste Asset Management GmbH 2,154,900 $81.97M 3.55% 3.68% 2026-06-30
10 NOMURA ASSET MANAGEMENT INTERNATIONAL INC. 2,110,809 $78.33M 3.39% 3.60% 2026-06-30
11 GEODE CAPITAL MANAGEMENT, LLC Custodian 1,574,268 $58.43M 2.53% 2.69% 2026-06-30
12 SUSQUEHANNA INTERNATIONAL GROUP, LLP Custodian 1,375,558 $51.05M 2.21% 2.35% 2026-06-30
13 ADAR1 Capital Management, LLC 1,288,053 $47.80M 2.07% 2.20% 2026-06-30
14 BNP Paribas Asset Management Holding S.A. 1,280,044 $47.50M 2.06% 2.18% 2026-06-30
15 DIMENSIONAL FUND ADVISORS LP Custodian 1,248,738 $46.35M 2.01% 2.13% 2026-06-30
16 GOLDMAN SACHS GROUP INC Custodian 1,150,932 $42.71M 1.85% 1.96% 2026-06-30
17 UBS Group AG Custodian 985,831 $36.58M 1.58% 1.68% 2026-06-30
18 MORGAN STANLEY Custodian 963,256 $35.75M 1.55% 1.64% 2026-06-30
19 Nuveen, LLC Custodian 873,560 $32.42M 1.40% 1.49% 2026-06-30
20 ARROWSTREET CAPITAL, LIMITED PARTNERSHIP 810,530 $30.08M 1.30% 1.38% 2026-06-30
21 Foresite Capital Management VI LLC 785,000 $29.13M 1.26% 1.34% 2026-06-30
22 CITADEL ADVISORS LLC Custodian 732,687 $27.19M 1.18% 1.25% 2026-06-30
23 AQR CAPITAL MANAGEMENT LLC Custodian 684,340 $25.40M 1.10% 1.17% 2026-06-30
24 Parkman Healthcare Partners LLC 669,046 $24.83M 1.07% 1.14% 2026-06-30
25 SCS Capital Management LLC 612,850 $22.74M 0.98% 1.05% 2026-06-30
12 filers$128.81M notional
# Filer Notional Value % of Total Period
1 ARMISTICE CAPITAL, LLC $104.28M 80.96% 2026-06-30
2 SUSQUEHANNA INTERNATIONAL GROUP, LLP Custodian $6.33M 4.92% 2026-06-30
3 CITADEL ADVISORS LLC Custodian $3.40M 2.64% 2026-06-30
4 Caligan Partners LP $3.34M 2.59% 2026-06-30
5 GROUP ONE TRADING LLC Custodian $2.19M 1.70% 2026-06-30
6 Tetragon Partners GP Ltd $1.86M 1.44% 2026-06-30
7 Caption Management, LLC $1.86M 1.44% 2026-06-30
8 SIMPLEX TRADING, LLC Custodian $1.48M 1.15% 2026-06-30
9 JANE STREET GROUP, LLC Custodian $1.45M 1.13% 2026-06-30
10 CITIGROUP INC Custodian $1.22M 0.95% 2026-06-30
11 BOOTHBAY FUND MANAGEMENT, LLC $950.02K 0.74% 2026-06-30
12 WOLVERINE TRADING, LLC Custodian $447.68K 0.35% 2025-09-30
7 filers$21.61M notional
# Filer Notional Value % of Total Period
1 JANE STREET GROUP, LLC Custodian $7.97M 36.91% 2026-06-30
2 SUSQUEHANNA INTERNATIONAL GROUP, LLP Custodian $5.08M 23.51% 2026-06-30
3 GROUP ONE TRADING LLC Custodian $3.64M 16.85% 2026-06-30
4 CITADEL ADVISORS LLC Custodian $3.30M 15.25% 2026-06-30
5 CITIGROUP INC Custodian $1.22M 5.67% 2026-06-30
6 SIMPLEX TRADING, LLC Custodian $378.52K 1.75% 2026-06-30
7 JPMORGAN CHASE & CO Custodian $11.41K 0.05% 2026-06-30
Insider Activity
Latest: 2026-08-06
Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
Filed Reporter Role Action Shares Avg Price Net $ Link
2026-08-06 Sarah Gheuens Chief Medical Officer Sell (S) −30,000 $30.48 -$914.4K EDGAR
2026-08-06 Sarah Gheuens Chief Medical Officer Sell (S) −30,000 $30.48 -$914.4K EDGAR
2026-07-10 Jay T. Backstrom Director Award (A) +1,447 EDGAR
2026-07-02 Sarah Gheuens Chief Medical Officer Mixed +4,368 $37.56 -$150.5K EDGAR
2026-06-23 Adams Catherine Owen Director Exer (M) +2,816 EDGAR
2026-06-23 Jay T. Backstrom Director Grant (A) +17,877 RSU EDGAR
2026-06-23 Krishnan Viswanadhan Chief Strategy and Operations Mixed EDGAR
2026-06-23 Sarah Gheuens Chief Medical Officer Mixed EDGAR
2026-06-23 Cecilia Jones Chief Financial Officer Mixed EDGAR
2026-06-23 Brian Goff Chief Executive Officer Mixed EDGAR
2026-06-23 JACQUALYN A FOUSE Director Exer (M) +2,816 EDGAR
2026-06-23 Rahul D. Ballal Director Exer (M) +2,816 EDGAR
2026-06-23 James William Burns Chief Legal Officer Mixed EDGAR
2026-06-23 David Scadden Director Exer (M) +2,816 EDGAR
2026-06-23 Cynthia Smith Director Exer (M) +2,816 EDGAR
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.
Insider Holdings
40 insiders · @ $33.60
Officers, directors, and 10%+ owners ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
# Insider Role Shares Disclosed Exposure Lifetime OM Net Filings Last Filed
1 CELGENE CORP /DE/ 10%+ Owner 6,718,433 $225.74M $618.13M 4 2018-01-31
2 Celgene European Investment Co LLC 10%+ Owner 5,788,750 $194.50M $75.32M 2 2019-11-14
3 Flagship Ventures Fund 2007, L.P. 10%+ Owner 3,860,738 $129.72M $0 1 2013-07-31
4 CLINTON BYBEE 10%+ Owner 3,088,590 $103.78M $0 2 2015-02-23
5 THIRD ROCK VENTURES LP 10%+ Owner 3,070,090 $103.16M $0 1 2014-09-12
6 KEVIN P STARR Director 944,581 $31.74M $0 3 2015-02-19
7 David P Schenkein Director 397,014 $13.34M -$62.02M 86 2024-06-24
8 Brian Goff Chief Executive Officer 177,604 $5.97M -$5.41M 16 2026-06-23
9 JACQUALYN A FOUSE Director 154,156 $5.18M $112.3K 24 2026-06-23
10 John Duncan Higgons Chief Operating Officer 120,834 $4.06M -$21.43M 34 2016-01-05
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.
Notice of Proposed Sale (Form 144)
Latest: 2026-08-04
Last 30d: 0 filings  ·  Last 90d: 2 filings · $1.1M notice value · 1 unique filer · 100% under 10b5-1 plans

What is Form 144? A notice of intent to sell restricted or control stock under Rule 144. Affiliates (officers, directors, 10%+ owners) and holders of restricted shares must file Form 144 when planning to sell more than 5,000 shares or $50,000 in any 3-month rolling window.

How it relates to Form 4: Form 144 is filed before the trade (up to 90 days in advance); Form 4 is filed within 2 business days after the trade executes. Not every Form 144 results in a sale — the filer may cancel or delay. Look for the corresponding Form 4 on the Insider Activity card to confirm a sale actually happened.

10b5-1 plans: Trades made under a pre-scheduled Rule 10b5-1 plan are not discretionary — they execute automatically on dates set months earlier, regardless of news. High 10b5-1 percentages mean less per-filing signal value, though cumulative selling volume still matters.

"Notice value": Aggregate market value the filer wrote into the Form 144 — i.e. the size of the planned sale, not necessarily the executed dollars. Amendments (Form 144/A) and post-cancellation refilings can inflate this if you sum naively; the rollup above excludes filings with zero stated value.

Source & freshness: Sourced from public Form 144 filings. Refreshed daily; new filings typically appear here the morning after they are filed.

Top 90-day filers: Gheuens Sarah (2, $1.1M)
Filed Filer Role Shares Notice Value Planned Sale Broker Plan Link
2026-08-04 SARAH GHEUENS Officer 30,000 $914.3K 2026-08-04 Morgan Stanley Smith Barney LLC … 10b5-1 EDGAR
2026-07-01 Gheuens Sarah Officer 4,007 $150.5K 2026-07-01 Morgan Stanley Smith Barney LLC … 10b5-1 EDGAR
2026-04-02 Goff Brian Officer, Director 19,068 $651.9K 2026-04-02 Morgan Stanley Smith Barney LLC … 10b5-1 EDGAR
2026-04-02 Jones Cecilia Officer 3,141 $107.4K 2026-04-02 Morgan Stanley Smith Barney LLC … 10b5-1 EDGAR
2026-04-02 Viswanadhan Krishnan Officer 2,959 $101.2K 2026-04-02 Morgan Stanley Smith Barney LLC … 10b5-1 EDGAR
2026-04-02 Milanova Tsveta Officer 3,262 $111.5K 2026-04-02 Morgan Stanley Smith Barney LLC … 10b5-1 EDGAR
2026-04-02 Gheuens Sarah Officer 2,940 $100.5K 2026-04-02 Morgan Stanley Smith Barney LLC … 10b5-1 EDGAR
2026-04-02 Burns James William Officer 3,280 $112.1K 2026-04-02 Morgan Stanley Smith Barney LLC … 10b5-1 EDGAR
2026-03-05 Viswanadhan Krishnan Officer 2,959 $85.8K 2026-03-05 Morgan Stanley Smith Barney LLC … 10b5-1 EDGAR
2026-03-02 Goff Brian Officer, Director 18,055 $545.8K 2026-03-02 Morgan Stanley Smith Barney LLC … 10b5-1 EDGAR
Notice value is the aggregate market value the filer states they intend to sell — not a confirmed transaction. Compare to Insider Activity (Form 4) to see which planned sales actually executed.
ETF Holders
# ETF Provider Weight $ Exposure ETF AUM As Of
Fundamentals

Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.

Metrics
  • Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
  • Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
  • Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
  • Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
  • Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
  • YoY growth — compare to the same quarter a year earlier to remove seasonality.
  • Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
  • Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.

TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.

P/B Ratio2.0
P/S Ratio20.4
EV/EBITDA-4.2
TTM Revenue$0.1B
TTM Net Income$-0.4B
TTM EPS$-7.01
ROE-40.1%